Formycon AG (FYB) - Net Assets
Based on the latest financial reports, Formycon AG (FYB) has net assets worth €399.14 Million EUR (≈ $466.63 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€739.53 Million ≈ $864.58 Million USD) and total liabilities (€340.39 Million ≈ $397.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FYB intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €399.14 Million |
| % of Total Assets | 53.97% |
| Annual Growth Rate | 49.51% |
| 5-Year Change | 614.13% |
| 10-Year Change | 1810.53% |
| Growth Volatility | 174.81 |
Formycon AG - Net Assets Trend (2009–2025)
This chart illustrates how Formycon AG's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Formycon AG to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Formycon AG (2009–2025)
The table below shows the annual net assets of Formycon AG from 2009 to 2025. For live valuation and market cap data, see Formycon AG market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €399.14 Million ≈ $466.63 Million |
-13.58% |
| 2024-12-31 | €461.84 Million ≈ $539.94 Million |
-8.14% |
| 2023-12-31 | €502.75 Million ≈ $587.77 Million |
+40.99% |
| 2022-12-31 | €356.58 Million ≈ $416.88 Million |
+537.99% |
| 2021-12-31 | €55.89 Million ≈ $65.34 Million |
-17.85% |
| 2020-12-31 | €68.04 Million ≈ $79.54 Million |
+41.12% |
| 2019-12-31 | €48.21 Million ≈ $56.36 Million |
+45.04% |
| 2018-12-31 | €33.24 Million ≈ $38.86 Million |
+30.13% |
| 2017-12-31 | €25.54 Million ≈ $29.86 Million |
+22.27% |
| 2016-12-31 | €20.89 Million ≈ $24.42 Million |
-16.00% |
| 2015-12-31 | €24.87 Million ≈ $29.08 Million |
+82.32% |
| 2014-12-31 | €13.64 Million ≈ $15.95 Million |
+11.35% |
| 2013-12-31 | €12.25 Million ≈ $14.32 Million |
+187.57% |
| 2012-12-31 | €4.26 Million ≈ $4.98 Million |
-17.07% |
| 2011-12-31 | €5.14 Million ≈ $6.01 Million |
+26.21% |
| 2010-12-31 | €4.07 Million ≈ $4.76 Million |
+535.98% |
| 2009-12-31 | €640.00K ≈ $748.23K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Formycon AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11605400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €17.67 Million | 4.43% |
| Other Components | €498.00 Million | 124.77% |
| Total Equity | €399.14 Million | 100.00% |
Formycon AG Competitors by Market Cap
The table below lists competitors of Formycon AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
First Bancorp Inc
NASDAQ:FNLC
|
$336.87 Million |
|
Interarch Building Products Limited
NSE:INTERARCH
|
$336.95 Million |
|
Ascencio (D)
BR:ASCE
|
$337.05 Million |
|
Eagle Bulk Shipping Inc
NYSE:EGLE
|
$337.10 Million |
|
NUIX Ltd
AU:NXL
|
$336.76 Million |
|
Castro
TA:CAST
|
$336.75 Million |
|
BRASI.CIA BRAS.D.PROP.ADR
F:52BA
|
$336.70 Million |
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
$336.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Formycon AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 461,843,000 to 399,136,000, a change of -62,707,000 (-13.6%).
- Net loss of 64,696,000 reduced equity.
- New share issuances of 176,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-64.70 Million | -16.21% |
| Share Issuances | €176.00K | +0.04% |
| Other Changes | €1.81 Million | +0.45% |
| Total Change | €- | -13.58% |
Book Value vs Market Value Analysis
This analysis compares Formycon AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.88x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 143.78x to 0.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €0.14 | €19.94 | x |
| 2010-12-31 | €0.41 | €19.94 | x |
| 2011-12-31 | €0.51 | €19.94 | x |
| 2012-12-31 | €0.43 | €19.94 | x |
| 2013-12-31 | €1.23 | €19.94 | x |
| 2014-12-31 | €1.52 | €19.94 | x |
| 2015-12-31 | €2.74 | €19.94 | x |
| 2016-12-31 | €2.30 | €19.94 | x |
| 2017-12-31 | €2.73 | €19.94 | x |
| 2018-12-31 | €3.53 | €19.94 | x |
| 2019-12-31 | €4.82 | €19.94 | x |
| 2020-12-31 | €6.19 | €19.94 | x |
| 2021-12-31 | €5.06 | €19.94 | x |
| 2022-12-31 | €25.68 | €19.94 | x |
| 2023-12-31 | €31.33 | €19.94 | x |
| 2024-12-31 | €26.40 | €19.94 | x |
| 2025-12-31 | €22.59 | €19.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Formycon AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -145.46%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.85x
- Recent ROE (-16.21%) is below the historical average (-14.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -29.84% | -955.00% | 0.03x | 1.10x | €-255.00K |
| 2010 | -24.79% | -2048.75% | 0.01x | 1.05x | €-1.42 Million |
| 2011 | -25.11% | 0.00% | 0.00x | 1.09x | €-1.80 Million |
| 2012 | -56.23% | -1730.29% | 0.02x | 1.79x | €-2.82 Million |
| 2013 | -63.19% | -2802.83% | 0.02x | 1.26x | €-8.97 Million |
| 2014 | 6.56% | 6.84% | 0.74x | 1.29x | €-450.78K |
| 2015 | 2.32% | 3.41% | 0.62x | 1.09x | €-1.91 Million |
| 2016 | -19.46% | -20.82% | 0.78x | 1.21x | €-6.16 Million |
| 2017 | -6.19% | -5.45% | 0.94x | 1.21x | €-4.14 Million |
| 2018 | 21.36% | 16.51% | 1.09x | 1.19x | €3.77 Million |
| 2019 | -4.76% | -6.92% | 0.62x | 1.11x | €-7.11 Million |
| 2020 | -9.89% | -19.66% | 0.45x | 1.11x | €-13.53 Million |
| 2021 | -23.78% | -36.30% | 0.52x | 1.27x | €-18.88 Million |
| 2022 | 10.09% | 84.69% | 0.05x | 2.39x | €334.00K |
| 2023 | 15.08% | 97.55% | 0.09x | 1.77x | €25.52 Million |
| 2024 | -27.21% | -180.37% | 0.09x | 1.67x | €-171.86 Million |
| 2025 | -16.21% | -145.46% | 0.06x | 1.85x | €-104.61 Million |
Industry Comparison
This section compares Formycon AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,825,018,023
- Average return on equity (ROE) among peers: -81.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Formycon AG (FYB) | €399.14 Million | -29.84% | 0.85x | $336.85 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $41.39 Million | -67.94% | 2.33x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-338.57 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $421.77 Million | -87.98% | 0.40x | $174.41 Million |
| PreveCeutical Medical Inc (18H) | $-5.78 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $7.32 Billion | 17.64% | 0.19x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.10 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $20.06 Billion | 47.04% | 0.16x | $20.05 Billion |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more